New Daily GLP-1 pill could replace weight loss injectables like Ozempic
April 17, 2025
42,814
563
30
1.39%
Search the Record
IndexedEvery word spoken in this episode is indexed. Type any phrase to jump straight to the moment it was said.
Type any word or phrase that may have been spoken. Click a result to seek the player to that exact moment.
Try a name, a topic, or a quoted line
Npr Episodes Around April 17, 2025
See what was published immediately before and after this episode.
0:59Now PlayingNew Daily GLP-1 pill could replace weight loss injectables like Ozempic
YouTube Description
as posted by the channelFor users of the popular weight loss injectables Ozempic, Wegovy, Zepbound and Mounjaro, a new GLP-1 pill may be on the horizon.
GLP-1 drugs have revolutionized the way the doctors treat weight loss — starting largely with Ozempic — Novo Nordisk’s blockbuster diabetes drug. But most of the current options on the market are injectables, which can be intimidating for patients to use.
Eli Lilly announced Thursday that early results from a Phase 3 clinical trial of its GLP-1 pill show it reduced participants’ A1C — a measure of blood sugar control — better than a placebo.
The trial lasted 40 weeks and only involved people with Type 2 diabetes. According to the company, the safety and efficacy was consistent with its injectable GLP-1 drugs, Zepbound and Mounjaro. The once-daily pill also helped patients lose up to 16 pounds.
Guests & Subjects Covered
Sentinel Indexing in Progress
Metadata and chapters are available. Claim extraction for this episode is pending.
All video content is delivered via YouTube embedded players in accordance with the YouTube Terms of Service. Sentinel provides research tools that promote discovery and accountability across political media.